AR079862A1 - Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion - Google Patents

Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion

Info

Publication number
AR079862A1
AR079862A1 ARP110100060A ARP110100060A AR079862A1 AR 079862 A1 AR079862 A1 AR 079862A1 AR P110100060 A ARP110100060 A AR P110100060A AR P110100060 A ARP110100060 A AR P110100060A AR 079862 A1 AR079862 A1 AR 079862A1
Authority
AR
Argentina
Prior art keywords
masked
pharmaceutical composition
flavor
taste
orally disintegrable
Prior art date
Application number
ARP110100060A
Other languages
English (en)
Inventor
Gopi M Venkatesh
Troy M Harmon
Original Assignee
Eurand Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurand Inc filed Critical Eurand Inc
Publication of AR079862A1 publication Critical patent/AR079862A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Reivindicacion 1: Una composicion farmacéutica con sabor enmascarado que comprende una cantidad terapéuticamente efectiva de partículas de monosacárido sustituido por sulfamato con sabor enmascarado que comprenden un monosacárido sustituido por sulfamato o una sal o derivado farmacéuticamente aceptable del mismo, en donde dichas partículas están recubiertas con una o más capas que enmascaran el sabor para enmascarar el sabor del monosacárido sustituido por sulfamato; en donde dicha(s) capa(s) que enmascara(n) el sabor comprende(n) al menos un polímero insoluble en agua. Reivindicacion 6: La composicion farmacéutica con sabor enmascarado de la reivindicacion 1 o el comprimido desintegrable oralmente de la reivindicacion 2, en donde dicho monosacárido sustituido por sulfamato o una sal o derivado farmacéuticamente aceptable del mismo es topiramato o una sal o derivado farmacéuticamente aceptable del mismo. Reivindicacion 21: La composicion farmacéutica con sabor enmascarado de la reivindicacion 1 o el comprimido desintegrable oralmente de la reivindicacion 2 que comprenden adicionalmente partículas que contienen fármaco con sabor enmascarado que comprenden un supresor del apetito de la clase las anfetaminas y/o feniletilaminas. Reivindicacion 22: La composicion farmacéutica con sabor enmascarado o el comprimido desintegrable oralmente de la reivindicacion 21 que comprende adicionalmente partículas con sabor enmascarado que comprenden vitamina B-12. Reivindicacion 23: La composicion farmacéutica con sabor enmascarado o el comprimido desintegrable oralmente de la reivindicacion 22 que comprende una cantidad efectiva de dichas partículas con sabor enmascarado que comprenden topiramato, fentermina y vitamina B-12. Reivindicacion 24: La composicion farmacéutica con sabor enmascarado de la reivindicacion 1 o el comprimido desintegrable oralmente de la reivindicacion 2 que comprenden adicionalmente partículas con sabor enmascarado que comprenden un antagonista del receptor de 5-HT3. Reivindicacion 26: La composicion farmacéutica con sabor enmascarado o el comprimido desintegrable oralmente de la reivindicacion 25 que comprenden una cantidad efectiva de dichas micropartículas con sabor enmascarado que comprenden topiramato, un antagonista del receptor de 5-HT3 y un antagonista del receptor opioide para el tratamiento del alcoholismo o la adiccion a drogas, en donde dicho antagonista del receptor de 5-HT3 es ondansetron o una sal farmacéuticamente aceptable del mismo y dicho antagonista del receptor opioide es naltrexona. Reivindicacion 35: Un método para tratar un paciente sometido a crisis tonico-clonicas de inicio parcial o generalizadas primarias, crisis asociadas con el síndrome Lennox-Gastaut y/o disfagia que comprende administrar al paciente una cantidad farmacéuticamente efectiva del comprimido desintegrable oralmente de la reivindicacion 2.
ARP110100060A 2010-01-08 2011-01-07 Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion AR079862A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29345510P 2010-01-08 2010-01-08

Publications (1)

Publication Number Publication Date
AR079862A1 true AR079862A1 (es) 2012-02-22

Family

ID=44305792

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110100060A AR079862A1 (es) 2010-01-08 2011-01-07 Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion

Country Status (5)

Country Link
US (1) US20110212171A1 (es)
AR (1) AR079862A1 (es)
TW (1) TW201127375A (es)
UY (1) UY33173A (es)
WO (1) WO2011085181A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
US8747895B2 (en) 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
EP1802285B1 (en) 2004-10-21 2013-02-27 Aptalis Pharmatech, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US9161918B2 (en) 2005-05-02 2015-10-20 Adare Pharmaceuticals, Inc. Timed, pulsatile release systems
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
WO2014144661A1 (en) * 2013-03-15 2014-09-18 Aprecia Pharmaceuticals Compny Rapidly dispersible dosage form of topiramate
JP6463333B2 (ja) 2013-03-15 2019-01-30 アプレシア・ファーマスーティカルズ・カンパニー オキシカルバゼピンの急速分散性の剤形
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
PL3157506T3 (pl) * 2014-06-20 2021-03-08 Hermes Arzneimittel Gmbh Kompozycja farmaceutyczna do podawania doustnego o maskowanym smaku
BR112018002046A2 (pt) * 2015-08-24 2018-09-18 Zogenix International Ltd métodos de tratamento da síndrome de lennox-gastaut usando fenfluramina
US10689324B2 (en) 2015-12-22 2020-06-23 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
SI3393655T1 (sl) 2015-12-22 2021-05-31 Zogenix International Limited Sestavki fenfluramina in metode priprave le-teh
CA3026611A1 (en) 2016-06-21 2017-12-28 Laila Nutraceuticals Taste masking formulation for bitter natural compounds
IL290727B2 (en) 2016-08-24 2023-12-01 Zogenix International Ltd A formulation for inhibiting the formation of 5–HT 2B agonists and methods of using it
US20180256515A1 (en) 2017-03-10 2018-09-13 Adare Pharmaceuticals, Inc. Oral amphetamine composition
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
CA3097335A1 (en) 2018-05-11 2019-11-14 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
US10517841B1 (en) 2018-06-14 2019-12-31 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
WO2020104837A1 (en) 2018-11-21 2020-05-28 Rosemont Pharmaceuticals Limited Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability
WO2020185214A1 (en) * 2019-03-12 2020-09-17 Balto Therapeutics Orally disintegrating tablets comprising glycopyrrolate and methods for increasing bioavailability
WO2021005501A1 (en) * 2019-07-10 2021-01-14 Intas Pharmaceuticals Ltd. Naltrexone formulation
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2246013A1 (de) * 1972-09-20 1974-03-28 Boehringer Mannheim Gmbh Verfahren zur herstellung von poroesen tabletten
US4078051A (en) * 1973-02-05 1978-03-07 L'oreal Cross-linked starch coated antiperspirant derivative of aluminum, process for its preparation and antiperspirant composition containing same
GB1548022A (en) * 1976-10-06 1979-07-04 Wyeth John & Brother Ltd Pharmaceutial dosage forms
US4292017A (en) * 1980-07-09 1981-09-29 Doepel Wallace A Apparatus for compressing tablets
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
JPS5916821A (ja) * 1982-07-16 1984-01-28 Tanabe Seiyaku Co Ltd 非凝集性マイクロカプセルの製法
US4698101A (en) * 1982-08-30 1987-10-06 Suomen Sokeri Oy (Finnish Sugar Company Ltd.) Binder-diluent composition and method
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
US4670459A (en) * 1984-10-03 1987-06-02 Merrell Dow Pharmaceuticals Inc. Method of alleviating withdrawal symptoms
FR2571045B1 (fr) * 1984-10-03 1987-12-11 Roquette Freres Mannitol granulaire directement compressible et son procede de fabrication
JPH0653658B2 (ja) * 1984-12-17 1994-07-20 中外製薬株式会社 安定な錠剤の製造法
DE3505433A1 (de) * 1985-02-16 1986-08-21 Basf Ag, 6700 Ludwigshafen Direkttablettierhilfsmittel
GB8530365D0 (en) * 1985-12-10 1986-01-22 Univ Bath Manufacture of moulded products
US5433959A (en) * 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
US4757090A (en) * 1986-07-14 1988-07-12 Mallinckrodt, Inc. Direct tableting acetaminophen compositions
US4760093A (en) * 1986-10-21 1988-07-26 American Home Products Corporation (Del.) Spray dried acetaminophen
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
US4874613A (en) * 1987-03-06 1989-10-17 Baker Cummins Pharmaceuticals, Inc. Taste concealing pharmaceutical dosage unit
US4851226A (en) * 1987-11-16 1989-07-25 Mcneil Consumer Products Company Chewable medicament tablet containing means for taste masking
US5211957A (en) * 1988-03-25 1993-05-18 Ciba-Geigy Corporation Solid rapidly disintegrating dosage form
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5256699A (en) * 1988-10-18 1993-10-26 Ciba-Geify Corporation Dispersible tablet formulation of diclofenac acid free base
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
US5104648A (en) * 1989-02-02 1992-04-14 Mallinckrodt Specialty Chemicals Company High ibuprofen content granulations
ATE114114T1 (de) * 1989-02-10 1994-12-15 Takeda Chemical Industries Ltd Verwendung von benzimidazol-derivaten als antibakterielle mittel.
US5084278A (en) * 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
US4946684A (en) * 1989-06-20 1990-08-07 American Home Products Corporation Fast dissolving dosage forms
US5082669A (en) * 1989-07-20 1992-01-21 Dainippon Pharmaceutical Co., Ltd. Rapid-releasing oral particle pharmaceutical preparation with unpleasant taste masked
US5079018A (en) * 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5039540A (en) * 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5178878A (en) * 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5013557A (en) * 1989-10-03 1991-05-07 Warner-Lambert Company Taste masking compositions comprising spray dried microcapsules containing sucralfate and methods for preparing same
IT1238078B (it) * 1990-01-31 1993-07-05 Silvano Spinelli Cis-platino complessi con ammine e sulfinilcarbossilati chelanti
IT1246383B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
US5286497A (en) * 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
CA2068402C (en) * 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
GB9113487D0 (en) * 1991-06-21 1991-08-07 Amersham Int Plc Agents for hypoxic cells
US5252337A (en) * 1991-06-25 1993-10-12 Eurand America, Inc. Controlled release calcium channel blocker microcapsules
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
DE69331839T2 (de) * 1992-01-29 2002-12-12 Takeda Chemical Industries, Ltd. Schnellösliche Tablette und ihre Herstellung
CA2128820A1 (en) * 1993-07-27 1995-01-28 Walter G. Gowan, Jr. Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof
DE4412117A1 (de) * 1994-04-08 1995-10-12 Fette Wilhelm Gmbh Verfahren und Vorrichtung zum Aufbringen von pulverförmigem Schmier- oder Trennmittel auf die Preßwerkzeuge in Tablettiermaschinen
ES2082723B1 (es) * 1994-07-20 1996-10-01 Lilly Sa Formulacion farmaceutica de fluoxetina en forma dispersable.
US5609883A (en) * 1994-09-16 1997-03-11 Advanced Technology Pharmaceuticals Corporation Compressed tablet transitory lubricant system
US5738875A (en) * 1994-10-28 1998-04-14 R.P. Scherer Corporation Process for preparing solid pharmaceutical dosage forms
US5639475A (en) * 1995-02-03 1997-06-17 Eurand America, Incorporated Effervescent microcapsules
WO1997004752A1 (en) * 1995-07-26 1997-02-13 Duramed Pharmaceuticals, Inc. Pharmaceutical compositions of conjugated estrogens and methods for their use
US5807577A (en) * 1995-11-22 1998-09-15 Lab Pharmaceutical Research International Inc. Fast-melt tablet and method of making same
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
US5762961A (en) * 1996-02-09 1998-06-09 Quadrant Holdings Cambridge Ltd. Rapidly soluble oral solid dosage forms, methods of making same, and compositions thereof
US20030064108A1 (en) * 1996-04-23 2003-04-03 Stefan Lukas Taste masked pharmaceutical compositions
EP1598061B1 (en) * 1996-06-14 2010-08-18 Kyowa Hakko Kirin Co., Ltd. Intraorally rapidly disintegrable tablet
CN1233954A (zh) * 1996-10-01 1999-11-03 西马实验室股份有限公司 掩盖味道的微胶囊组合物及其制备方法
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US5976577A (en) * 1997-07-11 1999-11-02 Rp Scherer Corporation Process for preparing fast dispersing solid oral dosage form
FR2766089B1 (fr) * 1997-07-21 2000-06-02 Prographarm Lab Comprime multiparticulaire perfectionne a delitement rapide
AR016827A1 (es) * 1997-08-22 2001-08-01 Smithkline Beecham Corp PROCEDIMIENTO PARA LA PREPARACIoN DE UNA TABLETA FARMACÉUTICA
US6221402B1 (en) * 1997-11-20 2001-04-24 Pfizer Inc. Rapidly releasing and taste-masking pharmaceutical dosage form
FR2771292B1 (fr) * 1997-11-21 2000-02-18 Ethypharm Lab Prod Ethiques Spheroides contenant de la tiagabine, procede de preparation et compositions pharmaceutiques
JPH11169437A (ja) * 1997-12-03 1999-06-29 Kyowa Hakko Kogyo Co Ltd 錠剤の製造方法
JP2002505269A (ja) * 1998-03-06 2002-02-19 エウランド インターナショナル ソシエタ ペル アチオニ 急速崩壊錠剤
JP4237405B2 (ja) * 1998-03-09 2009-03-11 シーマ・ラブス、インコーポレイテッド 集成体
US6465009B1 (en) * 1998-03-18 2002-10-15 Yamanouchi Pharmaceutical Co., Ltd. Water soluble polymer-based rapidly dissolving tablets and production processes thereof
US6350470B1 (en) * 1998-04-29 2002-02-26 Cima Labs Inc. Effervescent drug delivery system for oral administration
EP1121103B1 (en) * 1998-05-18 2006-12-20 Takeda Pharmaceutical Company Limited Orally disintegrable tablets comprising a benzimidazole
US6099865A (en) * 1998-07-08 2000-08-08 Fmc Corporation Croscarmellose taste masking
US6365182B1 (en) * 1998-08-12 2002-04-02 Cima Labs Inc. Organoleptically pleasant in-mouth rapidly disintegrable potassium chloride tablet
US6368625B1 (en) * 1998-08-12 2002-04-09 Cima Labs Inc. Orally disintegrable tablet forming a viscous slurry
US6296868B1 (en) * 1998-11-19 2001-10-02 Advanced Technology Pharmaceuticals Corporation Chewable tablets containing mannitol and aspartame
US6740341B1 (en) * 1998-11-25 2004-05-25 Cima Labs Inc. Taste masking rapid release coating system
US6284270B1 (en) * 1999-08-04 2001-09-04 Drugtech Corporation Means for creating a mass having structural integrity
US6420473B1 (en) * 2000-02-10 2002-07-16 Bpsi Holdings, Inc. Acrylic enteric coating compositions
US6627223B2 (en) * 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
AU2001244562A1 (en) * 2000-03-28 2001-10-08 Takeda Chemical Industries Ltd. Neovascularization inhibitors
US6551617B1 (en) * 2000-04-20 2003-04-22 Bristol-Myers Squibb Company Taste masking coating composition
US6368628B1 (en) * 2000-05-26 2002-04-09 Pharma Pass Llc Sustained release pharmaceutical composition free of food effect
US6344215B1 (en) * 2000-10-27 2002-02-05 Eurand America, Inc. Methylphenidate modified release formulations
JP5502254B2 (ja) * 2001-01-31 2014-05-28 エボニック レーム ゲゼルシャフト ミット ベシュレンクテル ハフツング 少なくとも２種類の異なる被覆ペレット形から成る多粒子剤形
US20040122106A1 (en) * 2001-03-06 2004-06-24 Motohiro Ohta Tablets quickly disintegrating in oral cavity
WO2002096392A1 (en) * 2001-05-31 2002-12-05 Cima Labs Inc. Taste-masking of highly water-soluble drugs
HRP20020923A2 (en) * 2001-11-23 2003-10-31 Glaxo Group Ltd Pharmaceutical composition
BR0312876A (pt) * 2002-07-25 2005-06-28 Pharmacia Corp Método de preparação de formas de dosagem sólidas revestidas em duas camadas compreendendo um polìmero insolúvel em água e um agente formador de poros solúvel em água
AU2004312059A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Atomoxetine formulations
US8545881B2 (en) * 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
WO2005120523A1 (en) * 2004-06-04 2005-12-22 Mood Management Sciences, Llc Methods and compositions for treating mood disorder
US8747895B2 (en) * 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
US9884014B2 (en) * 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
EP1802285B1 (en) * 2004-10-21 2013-02-27 Aptalis Pharmatech, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) * 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
WO2006063078A2 (en) * 2004-12-08 2006-06-15 Elan Corporation, Plc Topiramate pharmaceuticals composition
US20060233892A1 (en) * 2005-04-19 2006-10-19 Curt Hendrix Topiramate compositions for treatment of headache
JP5513113B2 (ja) * 2006-08-31 2014-06-04 アプタリス ファーマテック，インコーポレイテッド 弱塩基性薬剤の固溶体を含む薬剤送達システム

Also Published As

Publication number Publication date
US20110212171A1 (en) 2011-09-01
UY33173A (es) 2011-07-29
TW201127375A (en) 2011-08-16
WO2011085181A1 (en) 2011-07-14

Similar Documents

Publication Publication Date Title
AR079862A1 (es) Composicion de topiramato con sabor enmascarado, un comprimido desintegrable oralmente que comprende la misma y metodo de preparacion
AR124500A2 (es) Aumento de la biodisponibilidad de droga en terapia naltrexona
DK1982708T3 (en) Therapeutic agent for inflammatory bowel disease comprising 2-amino-1,3-propanediol derivative as active ingredient and method of treating inflammatory bowel disease
RU2013136350A (ru) Фармацевтическая композиция, содержащая опиоидный агонист и секвестрированный антагонист
HRP20150644T1 (hr) Metoda za lijeäśenje atrijalne fibrilacije
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
HRP20120317T1 (hr) Spojevi morfinana
FI3936130T3 (fi) Valbenatsiinin annostusohjelma hyperkineettisten liikehäiriöiden hoitoon
RS53995B1 (en) NEW ABUSE-RESISTANT PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF OPIOID SUBSTANCE
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
AR124497A2 (es) Métodos para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos métodos, y composición farmacéutica
EA200870449A1 (ru) Лечение воспалительных и язвенных заболеваний кишечника опиоидными антагонистами
JP2016509030A5 (es)
HRP20150809T1 (hr) Spojevi morfinana
EA200870182A1 (ru) Применение комбинации морфина и по меньшей мере одного антагониста опиатов для лечения зависимости от опиатов для предотвращения непероральной опиатомании у наркоманов
Olivier et al. Tramadol: Effects on sexual behavior in male rats are mainly caused by its 5-HT reuptake blocking effects
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
EA201101622A1 (ru) Пептидная фармацевтическая композиция, средство на ее основе для лечения гастродуоденальных заболеваний, вызываемых helicobacter pylori, и способ его использования
CA2958372A1 (en) Compositions for anti-inflammatory, antioxidant effects and improved respiratory function by specific histone deacetylase inhibition
RU2012129839A (ru) Комбинация теобромина с деконгестантом и ее применение для лечения кашля
US20240016790A1 (en) Methods of using a phenoxypropylamine compound to treat pain
AR088845A1 (es) Composiciones farmaceuticas que contienen 7-(1h-imidazol-4-ilmetil)-5,6,7,8-tetrahidro-quinolina para el tratamiento de las enfermedades y las afecciones de la piel
CN116808038A (zh) 阿片类物质和n-酰基乙醇胺的组合
ECSP11010999A (es) Combinación de dosis fija en la forma de una tableta de dos capas o de una sola capa de alisquireno y amlodipina
DK2091520T3 (da) Oral doseringsform omfattende trisubstituerede glycerol-forbindelser

Legal Events

Date Code Title Description
FB Suspension of granting procedure